177 related articles for article (PubMed ID: 25449805)
1. A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation.
Blaudszun AR; Moldenhauer G; Schneider M; Philippi A
J Control Release; 2015 Jan; 197():58-68. PubMed ID: 25449805
[TBL] [Abstract][Full Text] [Related]
2. Polyester-idarubicin nanoparticles and a polymer-photosensitizer complex as potential drug formulations for cell-mediated drug delivery.
Blaudszun AR; Lian Q; Schnabel M; Loretz B; Steinfeld U; Lee HH; Wenz G; Lehr CM; Schneider M; Philippi A
Int J Pharm; 2014 Oct; 474(1-2):70-9. PubMed ID: 25089507
[TBL] [Abstract][Full Text] [Related]
3. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
4. Polymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells.
Cohen EM; Ding H; Kessinger CW; Khemtong C; Gao J; Sumer BD
Otolaryngol Head Neck Surg; 2010 Jul; 143(1):109-15. PubMed ID: 20620628
[TBL] [Abstract][Full Text] [Related]
5. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
[TBL] [Abstract][Full Text] [Related]
6. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
[TBL] [Abstract][Full Text] [Related]
7. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
8. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
[TBL] [Abstract][Full Text] [Related]
9. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
10. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
11. Characterization and optimization of mTHPP nanoparticles for photodynamic therapy of head and neck cancer.
Ding H; Mora R; Gao J; Sumer BD
Otolaryngol Head Neck Surg; 2011 Oct; 145(4):612-7. PubMed ID: 21727244
[TBL] [Abstract][Full Text] [Related]
12. The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.
Hoh A; Dewerth A; Vogt F; Wenz J; Baeuerle PA; Warmann SW; Fuchs J; Armeanu-Ebinger S
Liver Int; 2013 Jan; 33(1):127-36. PubMed ID: 23088518
[TBL] [Abstract][Full Text] [Related]
13. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
Kobold S; Steffen J; Chaloupka M; Grassmann S; Henkel J; Castoldi R; Zeng Y; Chmielewski M; Schmollinger JC; Schnurr M; Rothenfußer S; Schendel DJ; Abken H; Sustmann C; Niederfellner G; Klein C; Bourquin C; Endres S
J Natl Cancer Inst; 2015 Jan; 107(1):364. PubMed ID: 25424197
[TBL] [Abstract][Full Text] [Related]
14. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
Haas C; Krinner E; Brischwein K; Hoffmann P; Lutterbüse R; Schlereth B; Kufer P; Baeuerle PA
Immunobiology; 2009; 214(6):441-53. PubMed ID: 19157637
[TBL] [Abstract][Full Text] [Related]
15. Photophysics and ex vivo biodistribution of β-cyclodextrin-meso-tetra(m-hydroxyphenyl)porphyrin conjugate for biomedical applications.
Kirejev V; Gonçalves AR; Aggelidou C; Manet I; Mårtensson J; Yannakopoulou K; Ericson MB
Photochem Photobiol Sci; 2014 Aug; 13(8):1185-91. PubMed ID: 24943653
[TBL] [Abstract][Full Text] [Related]
16. Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity.
Wu Y; Deng Z; Tang Y; Zhang S; Zhang YQ
BMC Cancer; 2015 Aug; 15():603. PubMed ID: 26310246
[TBL] [Abstract][Full Text] [Related]
17. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
[TBL] [Abstract][Full Text] [Related]
19. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
20. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]